US Patent

US10016443 — Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Method of Use · Assigned to Glenmark Specialty SA · Expires 2034-09-04 · 8y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating allergic rhinitis by nasally administering a fixed-dose combination of mometasone and olopatadine.

USPTO Abstract

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

Drugs covered by this patent

Elocon (MOMETASONE FUROATE) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3297`	—	Elocon

Patent Metadata

Patent number: US10016443
Jurisdiction: US
Classification: Method of Use
Expires: 2034-09-04
Drug substance claim: No
Drug product claim: No
Assignee: Glenmark Specialty SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.